Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers
NCT Number:
NCT03173950
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Brain and Nervous System
Study Objectives:
This study will test whether the immunotherapy drug nivolumab is an effective treatment for people with rare CNS tumors. The objective is to learn if stimulating the immune system using the drug nivolumab can shrink tumors in people with rare CNS (brain or spine) tumors or increase the time it takes for these tumors to grow or spread.
Study Documents
(MUSC NetID required for document access)